Immunotherapy combo shows promise in Hard-to-Treat rectal cancer
NCT ID NCT07005570
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding an immunotherapy drug (PD-1 antibody) and a blood vessel blocker (bevacizumab) to standard short-course radiotherapy and chemotherapy can improve outcomes for people with a common type of locally advanced rectal cancer (pMMR/MSS). About 86 participants will receive either the standard treatment or the enhanced combination. The main goal is to see if the tumor completely disappears before surgery, which could help some patients avoid surgery entirely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PD-1 monoclonal antibody and bevacizumab combined with chemotherapy (CAPOX regimen)
- What this could lead to
- If successful, this could improve the chance of complete tumor disappearance before surgery, potentially allowing some patients to avoid surgery altogether.
- What could go wrong
- This is a small, early-phase trial (86 participants) and the added immunotherapy may cause immune-related side effects. Results may not apply to all rectal cancer patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PMMR/MSS LOCALLY ADVANCED RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sixth Affiliated Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 610655, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.